Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26,027 | $22,123 | $18,790 | $15,529 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Cost of Goods Sold | $5,785 | $4,995 | $4,776 | $3,484 |
| Gross Profit | $20,242 | $17,128 | $14,014 | $12,045 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| R&D Expenses | $3,538 | $2,796 | $2,354 | $1,994 |
| G&A Expenses | $7,553 | $10,161 | $7,847 | $6,294 |
| SG&A Expenses | $11,085 | $10,161 | $7,847 | $6,294 |
| Sales & Mktg Exp. | $3,532 | $0 | $0 | $0 |
| Other Operating Expenses | -$6 | $105 | -$32 | -$30 |
| Operating Expenses | $14,617 | $13,062 | $10,169 | $8,258 |
| Operating Income | $5,625 | $4,066 | $3,813 | $3,733 |
| % Margin | 21.6% | 18.4% | 20.3% | 24% |
| Other Income/Exp. Net | -$1,218 | -$1,112 | -$492 | -$438 |
| Pre-Tax Income | $4,407 | $2,954 | $3,321 | $3,295 |
| Tax Expense | $528 | $546 | $683 | $616 |
| Net Income | $3,885 | $2,409 | $2,638 | $2,679 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS | 11.37 | 7.39 | 8.52 | 8.67 |
| % Growth | 53.9% | -13.3% | -1.7% | – |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| Weighted Avg Shares Out | 342 | 326 | 309 | 309 |
| Weighted Avg Shares Out Dil | 346 | 326 | 312 | 311 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $27 | $5 | $419 |
| Interest Expense | $1,239 | $1,111 | $458 | $0 |
| Depreciation & Amortization | $3,679 | $3,169 | $2,273 | $1,999 |
| EBITDA | $9,304 | $7,234 | $6,051 | $5,720 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |